News
Niagen Bioscience, Inc. Reports First Quarter 2025 Financial Results and Increases Outlook
Total net sales of $30.5 million, up $8.3 million or 38% year-over-year, gross margin of 63.4%, net income of $5.1 million and Adjusted EBITDA of $4.9 million for the three months ended March 31, 2025 and increased full year 2025 outlook. LOS ANGELES - Niagen...
Niagen Bioscience Announces Pharmaceutical-Grade Niagen® IV Is Now Available in Almost 600 Clinics Nationwide
Outperforming NAD+ IV, Niagen IV (patented nicotinamide riboside or NR) provides superior tolerability, a 75% shorter infusion time, and increases NAD+ 20% higher three hours post-infusion LOS ANGELES - Niagen Bioscience, Inc. (Nasdaq: NAGE) (formerly ChromaDex...
Niagen Bioscience Welcomes Dr. Pinchas Cohen to Scientific Advisory Board
Appointment of renowned gerontologist and mitochondrial biology expert underscores Niagen Bioscience's commitment to advancing cutting-edge NAD+ and healthspan research LOS ANGELES - Niagen Bioscience, Inc. (NASDAQ: NAGE) (formerly ChromaDex Corp.), the global...
Niagen Bioscience to Report First Quarter 2025 Financial Results on Wednesday, May 7, 2025
LOS ANGELES - Niagen Bioscience, Inc. (NASDAQ: NAGE) (formerly ChromaDex Corp.), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, announces that it will hold a conference call on Wednesday, May 7, 2025, at...
Niagen Bioscience Confirms Its Operations Remain Unaffected by New Tariffs
The Company's flagship patented nicotinamide riboside (NR) ingredient, Niagen®, is manufactured, encapsulated, and bottled in the U.S. and is currently classified as exempt from tariffs, minimizing exposure to tariff-related risks LOS ANGELES - Niagen Bioscience,...
Niagen Bioscience Confirms Its Operations Remain Resilient Amid New Tariff Developments
The Company's flagship patented nicotinamide riboside (NR) ingredient, Niagen®, is manufactured, encapsulated, and bottled in the U.S. and is currently classified as exempt from tariffs, minimizing exposure to tariff-related risks LOS ANGELES - Niagen Bioscience,...
Niagen Bioscience Secures U.S. Patent for the Composition of Matter for Nicotinamide Riboside (NR) Salt Forms
Exclusively licensed from Queen's University Belfast (QUB), this composition of matter patent, one of the most robust forms of intellectual property protection, grants Niagen Bioscience exclusive rights to various salt forms of NR and derivatives LOS ANGELES - Niagen...
ChromaDex Evolves Into Niagen Bioscience, Marking a New Era of Uncovering the Potential of NAD+ With Precision Science
The rebrand celebrates the company's clinically proven flagship patented nicotinamide riboside (NR) ingredient, Niagen, the most well-researched, efficient, high-quality, and legal NAD+ booster available LOS ANGELES - Niagen Bioscience, Inc. (Nasdaq: NAGE) (formerly...
ChromaDex Corp. Announces Name Change to Niagen Bioscience, Inc. and New Ticker Symbol “NAGE” Effective March 19, 2025
LOS ANGELES - ChromaDex Corp. (NASDAQ:CDXC), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, today announced that it will change its corporate name to Niagen Bioscience, Inc. and trade under the new Nasdaq...
ChromaDex to Present at the 37th Annual Roth Conference
LOS ANGELES - ChromaDex Corp. (NASDAQ: CDXC), the global authority on nicotinamide adenine dinucleotide (NAD+) with a focus on the science of healthy aging, today announces that senior management will participate at the 37th Annual ROTH Conference. ChromaDex CEO, Rob...